JP2020511462A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511462A5
JP2020511462A5 JP2019550557A JP2019550557A JP2020511462A5 JP 2020511462 A5 JP2020511462 A5 JP 2020511462A5 JP 2019550557 A JP2019550557 A JP 2019550557A JP 2019550557 A JP2019550557 A JP 2019550557A JP 2020511462 A5 JP2020511462 A5 JP 2020511462A5
Authority
JP
Japan
Prior art keywords
cells
inhibitor
less
pharmaceutical composition
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019550557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511462A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064362 external-priority patent/WO2018102785A2/en
Publication of JP2020511462A publication Critical patent/JP2020511462A/ja
Publication of JP2020511462A5 publication Critical patent/JP2020511462A5/ja
Priority to JP2022207877A priority Critical patent/JP2023036841A/ja
Withdrawn legal-status Critical Current

Links

JP2019550557A 2016-12-03 2017-12-01 キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物 Withdrawn JP2020511462A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022207877A JP2023036841A (ja) 2016-12-03 2022-12-26 キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662429732P 2016-12-03 2016-12-03
US62/429,732 2016-12-03
US201762581644P 2017-11-03 2017-11-03
US62/581,644 2017-11-03
PCT/US2017/064362 WO2018102785A2 (en) 2016-12-03 2017-12-01 Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022207877A Division JP2023036841A (ja) 2016-12-03 2022-12-26 キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2020511462A JP2020511462A (ja) 2020-04-16
JP2020511462A5 true JP2020511462A5 (https=) 2021-01-14

Family

ID=60955391

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019550557A Withdrawn JP2020511462A (ja) 2016-12-03 2017-12-01 キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物
JP2022207877A Pending JP2023036841A (ja) 2016-12-03 2022-12-26 キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022207877A Pending JP2023036841A (ja) 2016-12-03 2022-12-26 キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物

Country Status (9)

Country Link
US (2) US11590167B2 (https=)
EP (1) EP3548046A2 (https=)
JP (2) JP2020511462A (https=)
CN (1) CN110545826A (https=)
AU (1) AU2017368331A1 (https=)
CA (1) CA3045339A1 (https=)
MA (1) MA46995A (https=)
MX (2) MX2019006288A (https=)
WO (1) WO2018102785A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532997A (ja) * 2016-11-03 2019-11-14 ジュノー セラピューティクス インコーポレイテッド T細胞療法とbtk阻害剤との併用療法
CN118948892A (zh) * 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
KR20200003913A (ko) * 2017-05-10 2020-01-10 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
CN109136276A (zh) * 2018-09-30 2019-01-04 北京鼎成肽源生物技术有限公司 一种rfft2细胞的构建方法
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2020180733A1 (en) * 2019-03-01 2020-09-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
WO2021009510A1 (en) * 2019-07-16 2021-01-21 Autolus Limited Method for preconditioning a subject who is about to receive a t-cell therapy
JP2022554348A (ja) 2019-11-05 2022-12-28 ジュノー セラピューティクス インコーポレイテッド 治療用t細胞組成物の属性を決定する方法
JP2023520916A (ja) * 2020-04-08 2023-05-22 リミックス セラピューティクス インコーポレイテッド スプライシングを調整するための化合物及び方法
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
US20240173353A1 (en) * 2021-03-16 2024-05-30 Shanghai Iaso Biotechnology Co., Ltd. Universal chimeric antigen receptor t-cell and application thereof
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
UA83509C2 (en) 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US8101770B2 (en) 2004-12-16 2012-01-24 Vertex Pharmaceuticals Incorporated Pyridones useful as inhibitors of kinases
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
GB0624689D0 (en) 2006-12-11 2007-01-17 Glaxo Group Ltd Novel fluorescent kinase ligands and methods employing the same
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
TWI552752B (zh) 2007-10-19 2016-10-11 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
WO2009124119A2 (en) 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
PL2918604T3 (pl) 2008-11-07 2018-05-30 Amgen Research (Munich) Gmbh Leczenie pediatrycznej ostrej białaczki limfoblastycznej
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
NZ598985A (en) 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
TWI500617B (zh) 2010-05-31 2015-09-21 Ono Pharmaceutical Co Purine ketone derivatives
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
MX342164B (es) 2010-06-23 2016-09-19 Hanmi Science Co Ltd Derivados de pirimidina fusionados novedosos para la inhibicion de la actividad de tirosina cinasa.
MX336875B (es) 2010-08-10 2016-02-04 Celgene Avilomics Res Inc Sal de besilato de un inhibidor de tirosina cinasa de bruton (btk).
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
CN103073508B (zh) 2011-10-25 2016-06-01 北京大学深圳研究生院 激酶抑制剂及治疗相关疾病的方法
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP2773639B1 (en) 2011-11-03 2017-04-26 F. Hoffmann-La Roche AG Alkylated piperazine compounds as inhibitors of btk activity
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
US9199997B2 (en) 2011-11-29 2015-12-01 Ono Pharmaceutical Co., Ltd. Purinone derivative hydrochloride
KR20130076046A (ko) 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
CN104080789B (zh) 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
US9662343B2 (en) * 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
HRP20230297T1 (hr) 2012-07-13 2023-05-12 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
RU2658485C2 (ru) 2012-10-24 2018-06-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы м971
KR101668574B1 (ko) 2012-11-02 2016-10-24 화이자 인코포레이티드 브루톤 티로신 키나제 억제제
TW201427664A (zh) 2012-11-02 2014-07-16 Pharmacyclics Inc Tec家族激酶抑制劑佐劑療法
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
DK2940014T3 (en) 2012-12-28 2018-12-10 Crystalgenomics Inc 2,3-DIHYDRO-ISOINDOL-1-ON DERIVATIVE AS BTK KINase INHIBITORS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
EP2970985A1 (en) 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CN104177338B (zh) 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
TWI648272B (zh) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
BR112016006978A2 (pt) 2013-09-30 2017-08-01 Pharmacyclics Llc inibidores de tirosina quinase de bruton
WO2015057992A1 (en) 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015084892A1 (en) 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
US9931347B2 (en) 2013-12-03 2018-04-03 Iomet Pharma Ltd. Pharmaceutical compound
CN105979948A (zh) 2013-12-05 2016-09-28 安塞塔制药公司 Pi3k抑制剂和btk抑制剂的治疗组合
CN112353806A (zh) 2014-02-21 2021-02-12 普林斯匹亚生物制药公司 Btk抑制剂的盐和固体形式
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015146159A1 (en) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
US10611837B2 (en) 2014-04-10 2020-04-07 Seattle Children's Hospital Transgene genetic tags and methods of use
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN104829610B (zh) 2014-06-20 2017-03-15 中国科学院合肥物质科学研究院 一种新型布鲁顿酪氨酸激酶抑制剂
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
TW201618783A (zh) * 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
CN105884747B (zh) 2014-08-28 2021-01-05 首药控股(北京)有限公司 一种制备布鲁顿酪氨酸激酶(btk)激酶抑制剂的制备方法
CN105399756B (zh) 2014-09-05 2019-06-25 广东东阳光药业有限公司 Btk抑制剂及其用途
CN105153154A (zh) 2014-09-26 2015-12-16 广东东阳光药业有限公司 Btk抑制剂及其用途
CN105837576B (zh) 2015-01-14 2019-03-26 湖北生物医药产业技术研究院有限公司 Btk抑制剂
US9278919B1 (en) 2015-03-13 2016-03-08 Yong Xu Synthesis of N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Cd20療法、cd22療法、およびcd19キメラ抗原受容体(car)発現細胞との併用療法
CN104844573A (zh) 2015-04-17 2015-08-19 中国药科大学 嘧啶类btk抑制剂、其制备方法及医药用途
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
EP3747472B1 (en) 2015-09-15 2024-04-03 Acerta Pharma B.V. Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
TWI755547B (zh) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 靶向表皮生長因子受體變異體iii之嵌合型抗原受體
CN105732638B (zh) 2016-01-22 2018-01-30 成都倍特药业有限公司 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
CA3024725A1 (en) 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy
DK3523326T3 (da) 2016-10-04 2020-08-03 Prec Biosciences Inc Samstimulerende domæner til anvendelse i genetisk modificerede celler
JP2019532997A (ja) 2016-11-03 2019-11-14 ジュノー セラピューティクス インコーポレイテッド T細胞療法とbtk阻害剤との併用療法
BR112019017767A2 (pt) 2017-02-27 2020-04-07 Juno Therapeutics Inc composições, artigos de fabricação e métodos relacionados à dosagem em terapia celular
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP3621988A1 (en) 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
IL315340A (en) 2017-09-01 2024-10-01 Lonza Walkersville Inc End-to-end cell therapy automation
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
KR20210044736A (ko) 2018-05-03 2021-04-23 주노 쎄러퓨티크스 인코퍼레이티드 키메라 항원 수용체(car) t세포 요법과 키나제 억제제의 조합요법
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
US20210223248A1 (en) 2018-06-01 2021-07-22 Fred Hutchinson Cancer Research Center Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
CN113692285A (zh) 2018-11-30 2021-11-23 朱诺治疗学股份有限公司 在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
IL292665B2 (en) 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy

Similar Documents

Publication Publication Date Title
JP2020511462A5 (https=)
AU2023200557B2 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US11434293B2 (en) Anti TRBC1 antigen binding domains
US20240218075A1 (en) Use of chimeric antigen receptor modified cells to treat cancer
US20240360234A1 (en) Genetically modified natural killer cells for cd70-directed cancer immunotherapy
JP2019532997A5 (https=)
JP2022512971A5 (https=)
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
JP2020518591A5 (https=)
JP2019536460A5 (https=)
JP7162535B2 (ja) 抗gitr抗体およびその使用
WO2020033273A1 (en) Multi-function and multi-targeting car system and methods for use thereof
CN110520524A (zh) 靶向肿瘤微环境的嵌合抗原受体t细胞
WO2018102786A1 (en) Methods for modulation of car-t cells
US10654934B2 (en) Use of chimeric antigen receptor modified cells to treat cancer
CN114364801A (zh) 用于用抗bcma免疫治疗来治疗癌症的组合物和方法
CN110461363B (zh) 靶向cd37的嵌合抗原受体
JP2023522038A5 (https=)
JP2020533380A (ja) 癌の組合せ治療
WO2018064921A1 (en) Use of chimeric antigen receptor modified cells to treat cancer
JP2025524564A (ja) Cd19指向性がん免疫療法の投与レジメン
CN110540997B (zh) 靶向bcma嵌合抗原受体、核酸序列、载体及应用
WO2003072068A2 (en) Targeted immunotherapy of acute lymphoblastic leukemia (all)
Heß Checkpoint inhibition in non-Hodgkin's lymphoma
JP2016519075A (ja) Wt−1−陽性疾患のための組み合わせ/補助療法